Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE HYDROCHLORIDE vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
Not available.
None
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE HYDROCHLORIDE vs COLYTE, answered by our medical review team.
ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE HYDROCHLORIDE and COLYTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE HYDROCHLORIDE and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.